Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCapdevila Castillon, Jaume
dc.contributor.authorGrande, Enrique
dc.contributor.authorGarcia‑Carbonero, Rocio
dc.contributor.authorSimo Perdigo, Marc
dc.contributor.authorDel Olmo García, Maria Isabel
dc.contributor.authorJimenez-Fonseca, Paula
dc.contributor.authorCarmona-Bayonas, Alberto
dc.contributor.authorPubul Núñez, Virginia
dc.date.accessioned2022-08-18T10:30:55Z
dc.date.available2022-08-18T10:30:55Z
dc.date.issued2022-04
dc.identifier.citationCapdevila J, Grande E, García-Carbonero R, Simó M, Del Olmo-García MI, Jiménez-Fonseca P, et al. Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy. Oncologist. 2022 Apr;27(4):e328–39.
dc.identifier.issn1549-490X
dc.identifier.urihttp://hdl.handle.net/11351/8015
dc.descriptionNeoadjuvant therapy; Peptide receptor radionuclide therapy; Progression
dc.description.abstractBackground The aim of this study was to provide a guidance for the management of neuroendocrine tumors (NETs) in clinical practice. Material and Methods Nominal group and Delphi techniques were used. A steering committee of 8 experts reviewed the current management of NETs, identified controversies and gaps, critically analyzed the available evidence, and formulated several guiding statements for clinicians. Subsequently, a panel of 26 experts, was selected to test agreement with the statements through 2 Delphi rounds. Items were scored on a 4-point Likert scale from 1 = totally agree to 4 = totally disagree. The agreement was considered if ≥75% of answers pertained to Categories 1 and 2 (consensus with the agreement) or Categories 3 and 4 (consensus with the disagreement). Results Overall, 132 statements were proposed, which incorporated the following areas: (1) overarching principles; (2) progression and treatment response criteria; (3) advanced gastro-enteric NETs; (4) advanced pancreatic NETs; (5) advanced NETs in other locations; (6) re-treatment with radioligand therapy (RLT); (7) neoadjuvant therapy. After 2 Delphi rounds, only 4 statements lacked a clear consensus. RLT was not only recommended in the sequencing of different NETs but also as neoadjuvant treatment, while several indications for retreatment with RLT were also established. Conclusion This document sought to pull together the experts’ attitudes when dealing with different clinical scenarios of patients suffering from NETs, with RLT having a specific role where evidence-based data are limited.
dc.language.isoeng
dc.publisherOxford University Press
dc.relation.ispartofseriesThe Oncologist;27(4)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectTumors neuroendocrins - Radioteràpia
dc.subjectTumors neuroendocrins - Diagnòstic
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subject.meshNeuroendocrine Tumors
dc.subject.mesh/radiotherapy
dc.subject.meshTreatment Outcome
dc.titlePosition Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1093/oncolo/oyab041
dc.subject.decstumores neuroendocrinos
dc.subject.decs/radioterapia
dc.subject.decsresultado del tratamiento
dc.relation.publishversionhttps://doi.org/10.1093/oncolo/oyab041
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Capdevila J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron-Teknon Barcelona, Barcelona, Spain. [Grande E] Department of Medical Oncology, MD Anderson Cancer Center, Madrid, Spain. [García-Carbonero R] Department of Medical Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain. [Simó M] Servei de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Del Olmo-García MI] Department of Endocrinology, Hospital Universitario y Politécnico la Fe de Valencia, Valencia, Spain. [Jiménez-Fonseca P] Department of Medical Oncology, Hospital Universitario Central de Asturias, ISPA, Madrid, Spain. [Carmona-Bayonas A] Department of Hematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, Murcia, Spain. [Pubul V] Department of Nuclear Medicine Department, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
dc.identifier.pmid35380724
dc.identifier.wos000768544400001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record